EHA 2021 | Patient selection for CAR-T for pediatric B-ALL
Sara Ghorashian
• 11 Jun 2021
Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, gives an overview of considerations for the selection of pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) to receive the chimeric antigen receptor T-cell (CAR-T) therapy tisagenlecleucel. Dr Ghorashian outlines expanded access of tisagenlecleucel to patients under three in the UK in comparison to the cohort treated in the ELIANA study (NCT02435849). Dr Ghorashian also comments on the introduction of CAR-T therapy before stem cell transplantation and future research. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Sara Ghorashian, PhD, has received honoraria from Novartis.
